Rchr
J-GLOBAL ID:200901051623328580   Update date: Feb. 01, 2024

HIGASHI Morihiro

ヒガシ モリヒロ | HIGASHI Morihiro
Affiliation and department:
Job title: Professor
Research field  (2): Experimental pathology ,  Human pathology
Research theme for competitive and other funds  (4):
  • 2019 - 2023 Molecular function of LR11 in lipid metabolism of malignant lymphoma
  • 2022 - CD24を起点としたDLBCL腫瘍免疫微小環境改変機構の解明と治療開発 基盤の構築
  • 2015 - 2017 リツキシマブ細胞傷害におけるLR11の分子機構の解明
  • 2011 - 2014 Bリンパ腫におけるMatermindの役割
Papers (81):
  • Morihiro Higashi, Shuji Momose, Natsuko Takayanagi, Yuka Tanaka, Tomoe Anan, Takahisa Yamashita, Jun Kikuchi, Michihide Tokuhira, Masahiro Kizaki, Jun-Ichi Tamaru. CD24 is a surrogate for “immune-cold” phenotype in aggressive large B-cell lymphoma. The Journal of Pathology. 2022. 8. 4. 340-354
  • ◎Keisuke Sawada, Shuji Momose, Ryutaro Kawano, Masakazu Kohda, Tarou Irié, Kenji Mishima, Takahiro Kaneko, Norio Horie, Yasushi Okazaki, Morihiro Higashi & Jun-ichi Tamaru. Immunohistochemical staining patterns of p53 predict the mutational status of <I>TP53</I> in oral epithelial dysplasia. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2022. 35. 2. 177-185
  • Morihiro Higashi, Jun Kikuchi, Chiaki Murakami, Natsuko Takayanagi, Shuji Momose, Masahiro Kizaki, Jun-ichi Tamaru. Better method for detection of CD30: Immunohistochemistry or flow cytometry?. Journal of Clinical and Experimental Hematopathology. 2021. 61. 4. 221-223
  • Natsuko Takayanagi, Shuji Momose, Jun Kikuchi, Yuka Tanaka, Tomoe Anan, Takahisa Yamashita, Morihiro Higashi, Michihide Tokuhira, Masahiro Kizaki, Jun-ichi Tamaru. Fluorescent nanoparticle-mediated semiquantitative MYC protein expression analysis in morphologically diffuse large B-cell lymphoma. Pathology International. 2021. 71. 9. 594-603
  • Kumagai Y, Higashi M, Ishida H. Mucosal duodenal cancer originating from a Peutz-Jeghers polyp: Endocytoscopic features. Digestive Endoscopy. 2021. 33. 5. 870-871
more...
Books (10):
  • 古典的ホジキンリンパ腫「リンパ腫アトラス第5版」
    文光堂 2018
  • 分子生物学「リンパ腫アトラス第5版」
    文光堂 2018
  • 分子生物学 リンパ腫アトラス第5版
    文光堂 2018
  • 古典的ホジキンリンパ腫 リンパ腫アトラス第5版
    文光堂 2018
  • 総論 5. 分子生物学 悪性リンパ腫リンパ腫アトラス 改訂・改題 第4版
    文光堂 2014
more...
Lectures and oral presentations  (42):
  • 髄外病変を呈し3q26異常を認めた初発急性転化期慢性骨髄性白血病(de novo CML-BP)
    (第16回日本血液学会関東甲信越地方会 2022)
  • 口腔上皮性異形成における p53 の免疫組織化学的染色パターンが TP53 の変異状態を予測する
    (第67回日本病理学会秋期特別総会 2021)
  • Immunohistochemical staining patterns of p53 predict the mutational status of <I>TP53</I> in oral epithelial dysplasia
    (The 80th Annual Meeting of the Japanese Cancer Association 2021)
  • Successful bortezomib treatment for G-CSF-producing IgD-&λtype multiple myeloma.
    (The 83rd Annual Meeting of the Japanese Society of Hematology 2021)
  • A rare case of fat-free spindle cell/pleomorphic lipoma of the larynx.
    (2021)
more...
Education (1):
  • 1995 - 2000 Chiba University Post graduate School of Medicine Pathology
Professional career (1):
  • Ph. D (Chiba University)
Work history (8):
  • 2016/04/01 - 2018/03/31 Barcelona University, Hospital Clinic, Anatomical Pathology/IDIBAPS, Hematooncology Anatomical Patholgy/Hematooncology Researcher
  • 2016/04 - 2018/03 Barcelona University, Hospital Clinic, Anatomical Pathology/IDIBAPS, Hematooncology Anatomical Patholgy/Hematooncology Researher Postdoc
  • 2007/04 - 2009/03 Molecular and Tumor Pathology, Chiba University Graduate School of Medicine Assistant Professor
  • 2007/04 - 2009/03 Molecular and Tumor Pathology, Chiba University Graduate School of Medicine Assistant Professor
  • 2000/04 - 2007/03 First Dept. of Pathology, Chiba University Graduate School of Medicine Research Assistant
Show all
Committee career (3):
  • 2022/07 - 現在 日本リンパ網内系学会 学術評議員
  • 2007/07 - 現在 日本病理学会 学術評議員
  • 2008/04 - 2009/03 医学系CBT関連委員会医学系CBT実施小委員会 ブラッシュアップ専門部会
Awards (1):
  • 2011/09 - 第13回日本組織細胞化学会論文賞
Association Membership(s) (4):
日本リンパ網内系学会 ,  日本血液学会 ,  日本癌学会 ,  日本病理学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page